CA2599219C - Compositions and methods for treating and preventing cardiomyopathy and heart disease - Google Patents

Compositions and methods for treating and preventing cardiomyopathy and heart disease Download PDF

Info

Publication number
CA2599219C
CA2599219C CA2599219A CA2599219A CA2599219C CA 2599219 C CA2599219 C CA 2599219C CA 2599219 A CA2599219 A CA 2599219A CA 2599219 A CA2599219 A CA 2599219A CA 2599219 C CA2599219 C CA 2599219C
Authority
CA
Canada
Prior art keywords
composition
poloxamer
subject
present
heart
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2599219A
Other languages
English (en)
French (fr)
Other versions
CA2599219A1 (en
Inventor
Joseph Metzger
Dewayne Townsend
Soichiro Yasuda
Dan Michele
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of CA2599219A1 publication Critical patent/CA2599219A1/en
Application granted granted Critical
Publication of CA2599219C publication Critical patent/CA2599219C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2599219A 2005-02-25 2006-02-27 Compositions and methods for treating and preventing cardiomyopathy and heart disease Expired - Lifetime CA2599219C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65657005P 2005-02-25 2005-02-25
US60/656,570 2005-02-25
PCT/US2006/006862 WO2006091941A2 (en) 2005-02-25 2006-02-27 Compositions and methods for treating and preventing cardiomyopathy and heart disease

Publications (2)

Publication Number Publication Date
CA2599219A1 CA2599219A1 (en) 2006-08-31
CA2599219C true CA2599219C (en) 2011-09-20

Family

ID=36928113

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2599219A Expired - Lifetime CA2599219C (en) 2005-02-25 2006-02-27 Compositions and methods for treating and preventing cardiomyopathy and heart disease

Country Status (8)

Country Link
US (2) US7846426B2 (enExample)
EP (1) EP1853280B1 (enExample)
JP (1) JP5042041B2 (enExample)
AT (1) ATE546147T1 (enExample)
AU (2) AU2006216420B2 (enExample)
CA (1) CA2599219C (enExample)
ES (1) ES2380047T3 (enExample)
WO (1) WO2006091941A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5537152B2 (ja) * 2006-08-01 2014-07-02 フリクサス ファーマシューティカルズ， インコーポレイテッド 慢性進行性心不全のための処置
CA2682234A1 (en) * 2007-04-05 2008-10-16 Phrixus Pharmaceuticals, Inc. Compositions and methods for the treatment of heart failure
US20110052490A1 (en) * 2007-11-29 2011-03-03 Plur0Med, Inc Endoscopic mucosal resectioning using purified inverse thermosensitive polymers
EP2719389B1 (en) * 2007-12-17 2016-07-06 The Regents Of The University Of Michigan Compositions and methods for treating and preventing skeletal muscle deficiencies
US9867547B2 (en) 2012-11-29 2018-01-16 Siemens Healthcare Gmbh System and method to calculate cardiac characteristics
JP2016516825A (ja) * 2013-04-19 2016-06-09 シーダーズ−サイナイ メディカル センター 筋ジストロフィーの治療のためのホスホジエステラーゼ５ａ阻害物質
US20160235781A1 (en) * 2013-10-16 2016-08-18 Mast Therapeutics, Inc. Diuretic induced alterations of plasma volume
US9757411B2 (en) 2014-07-07 2017-09-12 Aires Pharmaceuticals, Inc. Poloxamer therapy for heart failure
TWI688392B (zh) 2014-07-07 2020-03-21 美商救生筏生物科技公司 無長循環材料之泊洛沙姆組成物以及其製造方法和用途
WO2016007542A1 (en) 2014-07-07 2016-01-14 Mast Therapeutics, Inc. Poloxamer therapy for heart failure
EP3965734A4 (en) * 2019-05-06 2022-12-14 Arshintseva, Elena Valentinovna Method for increasing cancer patient's haemoglobin level

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0576612B1 (en) * 1991-03-19 1999-12-01 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
JPH05178760A (ja) 1991-06-03 1993-07-20 Alpha Therapeutic Corp 心筋梗塞治療剤
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
US6761824B2 (en) * 2000-08-17 2004-07-13 Reeve Lorraine E Process for the fractionation of polymers
WO2002065834A2 (en) * 2000-10-24 2002-08-29 Smithkline Beecham Corporation Novel formulations of carvedilol

Also Published As

Publication number Publication date
AU2006216420B2 (en) 2010-07-15
US20110044935A1 (en) 2011-02-24
EP1853280A4 (en) 2008-10-29
JP2008531598A (ja) 2008-08-14
US8580245B2 (en) 2013-11-12
EP1853280A2 (en) 2007-11-14
AU2010214636A1 (en) 2010-09-16
US7846426B2 (en) 2010-12-07
ES2380047T3 (es) 2012-05-08
EP1853280B1 (en) 2012-02-22
WO2006091941A3 (en) 2007-01-04
ATE546147T1 (de) 2012-03-15
AU2006216420A1 (en) 2006-08-31
WO2006091941A2 (en) 2006-08-31
US20080260681A1 (en) 2008-10-23
CA2599219A1 (en) 2006-08-31
JP5042041B2 (ja) 2012-10-03

Similar Documents

Publication Publication Date Title
US8580245B2 (en) Compositions and methods for treating and preventing cardiomyopathy and heart disease
RU2503453C2 (ru) Фармацевтические композиции, обладающие желаемой биодоступностью
US20220273660A1 (en) Mek inhibitor for treatment of stroke
AU2013259526B2 (en) New methods
JP5560201B2 (ja) 骨格筋欠損症を治療および予防するための組成物および方法
WO2001068136A1 (en) Drugs for complications of diabetes and neuropathy and utilization thereof
FR3095755A1 (fr) Nouveaux médicaments cytoprotecteurs
CN101500557A (zh) 用于治疗癌症和血管发生的硝基呋喃化合物
KR20180127493A (ko) 승모판 질환으로 인한 무증상 심부전이 있는 환자에서 심장 크기의 감소 및/또는 임상적 증상 개시의 지연을 위한 피모벤단의 용도
US9155758B2 (en) Treatment of chronic progressive heart failure
JP2010505796A (ja) ネコの全身性疾患の予防又は治療の為のアンジオテンシンｉｉ受容体アンタゴニスト
BR112019012299A2 (pt) formulações farmacêuticas para o tratamento de glaucoma e métodos para a fabricação e uso das mesmas
US20240139181A1 (en) Methods for inducing pupil dilation
US11911384B2 (en) Vasodilators for treatment of heart failure
JP2004002370A (ja) 重症セプシス予防治療剤
JP4966019B2 (ja) 慢性移植片対宿主症におけるドライアイの予防および治療剤
JP4733348B2 (ja) 心不全、他の加齢関連臓器機能不全および加齢関連障害の予防のための、ならびに寿命を延長するための、ナトリウム−水素交換阻害剤であるカリポライドとａｃｅ阻害剤との組み合わせ製剤
US20240374557A1 (en) Beta adrenergic receptor compositions and methods of use thereof
WO2011066201A2 (en) Methods and systems for treating and preventing cardiac injury in dystrophic subjects
WO2016044902A1 (en) Pharmaceutical composition of 15-deoxy-delta-12,14-prostaglandin j2 in a poloxamer-based micellar system and its use for treatment of inflammatory conditions
WO2024151866A1 (en) Formulations and methods of treatment for hypertrophic cardiomyopathy
RU2021130472A (ru) Твердые фармацевтические композиции для лечения hcv

Legal Events

Date Code Title Description
EEER Examination request
H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250827

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251106